HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: FDA reform

This article was originally published in The Rose Sheet

Executive Summary

FDA reform: House FDA reform leadership has conceded that FDA reform will not move this year. House Commerce Committee/Health Subcommittee mark-up of the three-part bill was postponed once again in August until Congress resumed its session in September following the summer recess ("The Rose Sheet" Aug. 5, p. 11.) The measure has been tagged as a priority for next year. Commerce Committee Counsel John Cohrssen told a Food & Drug Law Institute meeting Sept. 5 that work would still continue through September on the measure. Senate efforts on a substitute amendment for FDA reform legislation (S 1477) continue as well; a memo sent the week of Sept. 2 to Senate Labor & Human Resources staff indicates that Sen. Kassebaum (R-Kan.) still hopes to bring FDA reform to the floor...
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS003222

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel